New research is freely available through Crystal Research Associates’ Research Library on MedeFile International Inc. (MDFI-OTCQB). Visit our library for the comprehensive 52-page PDF on MedeFile, a provider of Internet-enabled personal health records.
MedeFile is a healthcare information technology (IT) company that develops and markets its branded product, called MedeFile, which is a proprietary web-based system for storing personal health records (PHRs). MedeFile is a full-service solution that collects members’ actual medical records from a variety of sources and then organizes and electronically stores these documents in a secure, central location. Members can access information, anywhere and at any time, through multiple channels, including via a secure Internet portal and/or web-enabled mobile device, as well as through the Company’s patent-pending MedeDrive™, which is a specially designed Universal Serial Bus (USB) drive.
MedeFile’s flexible design allows subscribers to tailor the system to their needs—selecting what information is collected and from where, and defining rules for sharing that information with third parties, such as physicians, pharmacists, family members, or caretakers. The MedeFile solution also entails additional services, such as an interactive health calendar, a reminder service for medications and appointments, and a drug-to-drug interaction module. The Company believes that MedeFile’s multiple access points, unlimited storage space, automatically updated records, portability, and privacy features provide a competitive advantage in the marketplace.
Today, a company under our research coverage, WordLogic Corp. (WLGC-OTC) announced that the Texas Technology Access Program of the University of Texas at Austin selected the WordLogic Predictive Keyboard for use in its 16 statewide demonstration centers. The text of the press release is included below.
For more information about WordLogic Corporation, visit Crystal Research Associates’ Research Library page for WordLogic, which contains a 48-page complimentary research report on the Company.
VANCOUVER, British Columbia, June 2, 2011 (GLOBE NEWSWIRE) — The Texas Technology Access Program of the University of Texas at Austin has selected the WordLogic Predictive Keyboard product, a universal, easy-to-use text entry system for use in its 16 statewide demonstration centers to help students with learning disabilities, workforce retraining, and aiding disabled persons live more productive lives, reports WordLogic CEO Frank Evanshen.
The WordLogic Predictive Keyboard will also be used by Easter Seals and in Independent Living Centers run as part of the University’s Texas Technology Access Program, which is supported by the US Department of Education Rehabilitative Services Administration (RSA) under the Federal Assistive Technology Act of 2004.
“WordLogic technology has long been the technology product of choice for individuals with learning and physical disabilities who are seeking to improve and accelerate their keyboard- based communication skills,” says Mr. Evanshen. “It is our expectation that more state rehabilitative programs and universities will now take the lead from Texas to use WordLogic technology to help those in need.”
WordLogic’s predictive text entry software uses Intelligent Input Platform Technology to make it intuitive, fast, accurate, and helpful. WordLogic features:
- Intuitive drill-down prediction
- Exclusive multi-word, phrase and fragment prediction
- Probable next key color-highlighting
- Predicts accurately and learns based on individual usage
- Supports concurrent mixed languages (e.g. English/Espanyol/industry terms)
- WordLogic runs on any desktop computer
- WordLogic also runs on finger touchscreens, QWERTY keyboard and keypads, as well as on some smartphones and feature phones
Today, we published a Quarterly Update on GenSpera, Inc., a biotechnology company developing targeted prodrugs for prostate and other cancers. The Company’s prodrug technologies were developed over 15 years at Johns Hopkins and other global research centers and funded by over $15 million in grants from the U.S. National Institutes of Health, the National Cancer Institute, and the U.S. Department of Defense, among others.
A Phase I safety trial evaluating the Company’s lead prodrug candidate, G-202, in solid tumors is ongoing at three major cancer centers:
- the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland;
- the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin; and
- the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) in San Antonio, Texas.
To date, 16 patients have been enrolled and dosed in the Phase I study with G-202. The Company has the option to expand the trial to include 18 additional patients in a Phase Ib cohort at the maximum tolerated dose of G-202. Data from this cohort could provide an early signal of potential activity in multiple cancer types.
GenSpera’s pipeline is developing two additional prodrugs G-115 and G-301 (formerly Ac-GKAFRR-L12ADT), which directly target prostate cancer. The Company aims to obtain an Investigational New Drug (IND) for G-115 in the second half of 2011.
GenSpera has raised a total of $6.2 million to date in 2011, which is being used to support a Phase II clinical program with G-202 as well as the preclinical development of G-115. The Company owns and controls all rights to G-202, G-115, and G-301, and seeks strategic partnerships to maximize the value of its prodrugs.
A more detailed overview of GenSpera, as well as a summary of the Company’s stock information, is available through our Research Library.